

## REFERENCES

- Abedon, S. T., & Bartom, E. (2013, January 1). *Multiplicity of Infection* (S. Maloy & K. Hughes, Eds.). ScienceDirect; Academic Press.  
<https://www.sciencedirect.com/science/article/abs/pii/B978012374984000989X>
- Adon, T., Shanmugarajan, D., & Kumar, H. Y. (2021). CDK4/6 inhibitors: a brief overview and prospective research directions. *RSC Advances*, *11*(47), 29227–29246.  
<https://doi.org/10.1039/d1ra03820f>
- Alcázar-Fabra, M., Navas, P., & Brea-Calvo, G. (2016). Coenzyme Q biosynthesis and its role in the respiratory chain structure. *Biochimica et Biophysica Acta (BBA) - Bioenergetics*, *1857*(8), 1073–1078. <https://doi.org/10.1016/j.bbabi.2016.03.010>
- Alhmoud, J. F., Woolley, J. F., Al Moustafa, A.-E., & Malki, M. I. (2020). DNA Damage/Repair Management in Cancers. *Cancers*, *12*(4), 1050. <https://doi.org/10.3390/cancers12041050>
- Alva, E., Rubens, J., Chi, S., Rosenberg, T., Reddy, A., Raabe, E. H., & Margol, A. (2023). Recent progress and novel approaches to treating atypical teratoid rhabdoid tumor. *Neoplasia*, *37*, 100880. <https://doi.org/10.1016/j.neo.2023.100880>
- Alver, B. H., Kim, K. H., Lu, P., Wang, X., Manchester, H. E., Wang, W., Haswell, J. R., Park, P. J., & Roberts, C. W. M. (2017). The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers. *Nature Communications*, *8*(1). <https://doi.org/10.1038/ncomms14648>
- Avery, V. M., Camp, D., Carroll, A. R., Jenkins, I. D., & Quinn, R. J. (2010). The Identification of Bioactive Natural Products by High Throughput Screening (HTS). *Comprehensive Natural Products II*, *3*, 177–203. <https://doi.org/10.1016/b978-008045382-8.00062-9>
- Bae, J. S., Park, J. W., Park, S. H., Park, J. B., Rho, Y. H., Ryu, Y. B., Lee, K. S., Park, K. H., & Bae, Y. S. (2009). Apoptotic cell death of human leukaemia U937 cells by ubiquinone-9 purified from *Pleurotus eryngii*. *Natural Product Research*, *23*(12), 1112–1119.  
<https://doi.org/10.1080/14786410802417107>

- Bandara, A. B., Drake, J. C., & Brown, D. A. (2021). Complex II subunit SDHD is critical for cell growth and metabolism, which can be partially restored with a synthetic ubiquinone analog. *BMC Molecular and Cell Biology*, 22(1). <https://doi.org/10.1186/s12860-021-00370-w>
- Bannister, A. J., & Kouzarides, T. (2011). Regulation of Chromatin by Histone Modifications. *Cell Research*, 21(3), 381–395. <https://doi.org/10.1038/cr.2011.22>
- Bialkowska, A. B., & Yang, V. W. (2012). High-throughput screening strategies for targeted identification of therapeutic compounds in colorectal cancer. *Future oncology (London, England)*, 8(3), 259–272. <https://doi.org/10.2217/fon.12.19>
- Biegel, J. A. (2006). Molecular genetics of atypical teratoid/rhabdoid tumors. *Neurosurgical Focus*, 20(1), 1–7. <https://doi.org/10.3171/foc.2006.20.1.12>
- Betz, B. L., Strobeck, M. W., Reisman, D., Knudsen, E., & Weissman, B. E. (2002). Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1arrest associated with induction of p16ink4a and activation of RB. *Oncogene*, 21(34), 5193–5203. <https://doi.org/10.1038/sj.onc.1205706>
- Blessing, M. M., & Alexandrescu, S. (2020). Embryonal Tumors of the Central Nervous System. *Surgical Pathology Clinics*, 13(2), 235–247. <https://doi.org/10.1016/j.path.2020.01.003>
- Bock, C., Datlinger, P., Chardon, F., Coelho, M. A., Dong, M. B., Lawson, K. A., Lu, T., Maroc, L., Norman, T. M., Song, B., Stanley, G., Chen, S., Garnett, M., Li, W., Moffat, J., Qi, L. S., Shapiro, R. S., Shendure, J., Weissman, J. S., & Zhuang, X. (2022). High-content CRISPR screening. *Nature Reviews Methods Primers*, 2(1). <https://doi.org/10.1038/s43586-021-00093-4>
- Bokhari, F. F., & Albukhari, A. (2021). Design and Implementation of High Throughput Screening Assays for Drug Discoveries. In *www.intechopen.com*. IntechOpen. <https://www.intechopen.com/chapters/77492>
- Cash, T. (2023, October 10). *Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors (AflacST1501)*. Identifier NCT02644460. <https://clinicaltrials.gov/ct2/show/NCT02644460>

- Chai, J., Charboneau, A. L., Betz, B. L., & Weissman, B. E. (2005). Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. *Cancer Research*, *65*(22), 10192–10198. <https://doi.org/10.1158/0008-5472.CAN-05-1896>
- Chi, S. N., Zimmerman, M. A., Yao, X., Cohen, K. J., Burger, P., Biegel, J. A., Rorke-Adams, L. B., Fisher, M. J., Janss, A., Mazewski, C., Goldman, S., Manley, P. E., Bowers, D. C., Bendel, A., Rubin, J., Turner, C. D., Marcus, K. J., Goumnerova, L., Ullrich, N. J., & Kieran, M. W. (2009). Intensive Multimodality Treatment for Children With Newly Diagnosed CNS Atypical Teratoid Rhabdoid Tumor. *Journal of Clinical Oncology*, *27*(3), 385–389. <https://doi.org/10.1200/JCO.2008.18.7724>
- Chicco, D., Warrens, M. J., & Jurman, G. (2021). The coefficient of determination R-squared is more informative than SMAPE, MAE, MAPE, MSE and RMSE in regression analysis evaluation. *PeerJ Computer Science*, *7*(5), e623. <https://doi.org/10.7717/peerj-cs.623>
- Cocito, C., Martin, B., Larsen, A. G., Valcarce-Aspegren, M., Souweidane, M. M., Szalontay, L., Dahmane, N., & Greenfield, J. P. (2023). Leptomeningeal dissemination in pediatric brain tumors. *Neoplasia*, *39*, 100898–100898. <https://doi.org/10.1016/j.neo.2023.100898>
- Dharia, N. V., Kugener, G., Guenther, L. M., Malone, C. F., Durbin, A. D., Hong, A. L., Howard, T. P., Bandopadhyay, P., Wechsler, C. S., Fung, I., Warren, A. C., Dempster, J. M., Krill-Burger, J. M., Paolella, B. R., Moh, P., Jha, N., Tang, A., Montgomery, P., Boehm, J. S., & Hahn, W. C. (2021). A first-generation pediatric cancer dependency map. *Nature Genetics*, *53*(4), 529–538. <https://doi.org/10.1038/s41588-021-00819-w>
- Egiz, A., Kannan, S., & Asl, S. F. (2022). The impact of surgical resection and adjuvant therapy on survival in paediatric patients with Atypical Teratoid Rhabdoid Tumour: Systematic review and pooled survival analysis. *World Neurosurgery*. <https://doi.org/10.1016/j.wneu.2022.04.073>

- Filbin, M., & Monje, M. (2019). Developmental origins and emerging therapeutic opportunities for childhood cancer. *Nature Medicine*, 25(3), 367–376. <https://doi.org/10.1038/s41591-019-0383-9>
- Fleming, A. J., Hukin, J., Rassekh, R., Fryer, C., Kim, J., Stemmer-Rachamimov, A., Birks, D. K., Huang, A., Yip, S., & Dunham, C. (2012). Atypical Teratoid Rhabdoid Tumors (ATRTs): The British Columbia's Children's Hospital's Experience, 1986–2006. *Brain Pathology*, 22(5), 625–635. <https://doi.org/10.1111/j.1750-3639.2011.00561.x>
- Forth, S., & Kapoor, T. M. (2017). The mechanics of microtubule networks in cell division. *The Journal of Cell Biology*, 216(6), 1525–1531. <https://doi.org/10.1083/jcb.201612064>
- Fujisawa, H., Misaki, K., Takabatake, Y., Hasegawa, M., & Yamashita, J. (2005). Cyclin D1 is overexpressed in atypical teratoid/rhabdoid tumor with hSNF5/INI1 gene inactivation. *Journal of Neuro-Oncology*, 73(2), 117–124. <https://doi.org/10.1007/s11060-004-4276-4>
- Gadd, S., Sredni, S. T., Huang, C. C., & Perlman, E. J. (2010). Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets. *Laboratory Investigation*, 90(5), 724–738. <https://doi.org/10.1038/labinvest.2010.66>
- Gajjar, A. (2023, October 10). *Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (SJATRT)*. Identifier NCT02114229. <https://clinicaltrials.gov/ct2/show/NCT02114229>
- Ginn, K. F., & Gajjar, A. (2012). Atypical Teratoid Rhabdoid Tumor: Current Therapy and Future Directions. *Frontiers in Oncology*, 2. <https://doi.org/10.3389/fonc.2012.00114>
- Geyer, J. R., Sposto, R., Jennings, M., Boyett, J. M., Axtell, R. A., Breiger, D., Broxson, E., Donahue, B., Finlay, J. L., Goldwein, J. W., Heier, L. A., Johnson, D., Mazewski, C., Miller, D. C., Packer, R., Puccetti, D., Radcliffe, J., Tao, M. L., & Shiminski-Maher, T. (2005). Multiagent Chemotherapy and Deferred Radiotherapy in Infants With Malignant Brain Tumors: A Report From the Children's Cancer Group. *Journal of Clinical Oncology*, 23(30), 7621–7631. <https://doi.org/10.1200/jco.2005.09.095>

- Gupta, N., Hanley, M. J., Xia, C., Labotka, R., Harvey, R. D., & Venkatakrisnan, K. (2018). Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. *Clinical Pharmacokinetics*, 58(4), 431–449. <https://doi.org/10.1007/s40262-018-0702-1>
- Haberler, C., Laggner, U., Slavc, I., Czech, T., Ambros, I. M., Ambros, P. F., Budka, H., & Hainfellner, J. A. (2006). Immunohistochemical Analysis of INI1 Protein in Malignant Pediatric CNS Tumors: Lack of INI1 in Atypical Teratoid/Rhabdoid Tumors and in a Fraction of Primitive Neuroectodermal Tumors without Rhabdoid Phenotype. *The American Journal of Surgical Pathology*, 30(11), 1462–1468. <https://doi.org/10.1097/01.pas.0000213329.71745.ef>
- Han, Z.Y., Richer, W., Fréneaux, P., Chauvin, C., Lucchesi, C., Guillemot, D., Grison, C., Lequin, D., Pierron, G., Julien Masliah-Planchon, Nicolas, A., Ranchère-Vince, D., Pascale Varlet, Stéphanie Puget, Janoueix-Lerosey, I., Olivier Ayrault, Surdez, D., Delattre, O., & Franck Bourdeaut. (2016). The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation. *Nature Communications*, 7(1). <https://doi.org/10.1038/ncomms10421>
- Hasselblatt, M., Gesk, S., Oyen, F., Rossi, S., Viscardi, E., Giangaspero, F., Giannini, C., Judkins, A. R., Frühwald, M. C., Obser, T., Schneppenheim, R., Siebert, R., & Paulus, W. (2011). Nonsense Mutation and Inactivation of SMARCA4 (BRG1) in an Atypical Teratoid/Rhabdoid Tumor Showing Retained SMARCB1 (INI1) Expression. *American Journal of Surgical Pathology*, 35(6), 933–935. <https://doi.org/10.1097/pas.0b013e3182196a39>
- Hilden, J. M., Meerbaum, S., Burger, P., Finlay, J., Janss, A., Scheithauer, B. W., Walter, A. W., Rorke, L. B., & Biegel, J. A. (2004). Central Nervous System Atypical Teratoid/Rhabdoid Tumor: Results of Therapy in Children Enrolled in a Registry. *Journal of Clinical Oncology*, 22(14), 2877–2884. <https://doi.org/10.1200/jco.2004.07.073>
- Hirano, M. (2012, July -). *Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes (MELAS)*. Identifier NCT00887562. <https://clinicaltrials.gov/ct2/show/CT00887562>

- Holdhof, D., Johann, P. D., Spohn, M., Bockmayr, M., Safaei, S., Joshi, P., Masliah-Planchon, J., Ho, B., Andrianteranagna, M., Bourdeaut, F., Huang, A., Kool, M., Upadhyaya, S. A., Bendel, A. E., Indenbirken, D., Foulkes, W. D., Bush, J. W., Creytens, D., Kordes, U., & Frühwald, M. C. (2020). Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases. *Acta Neuropathologica*, *141*(2), 291–301. <https://doi.org/10.1007/s00401-020-02250-7>
- Jackson, E. M., Sievert, A. J., Gai, X., Hakonarson, H., Judkins, A. R., Tooke, L., Perin, J. C., Xie, H., Shaikh, T. H., & Biegel, J. A. (2009). Genomic Analysis Using High-Density Single Nucleotide Polymorphism-Based Oligonucleotide Arrays and Multiplex Ligation-Dependent Probe Amplification Provides a Comprehensive Analysis of *INI1/SMARCB1* in Malignant Rhabdoid Tumors. *Clinical Cancer Research*, *15*(6), 1923–1930. <https://doi.org/10.1158/1078-0432.ccr-08-2091>
- Johann, P. D., Erkek, S., Zapatka, M., Kerl, K., Buchhalter, I., Hovestadt, V., Jones, D. T. W., Sturm, D., Hermann, C., Wang, M. S., Korshunov, A., Rhyzova, M., Gröbner, S., Brabetz, S., Chavez, L., Bens, S., Gröschel, S., Kratochwil, F., Wittmann, A., & Sieber, L. (2016). Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. *Cancer Cell*, *29*(3), 379–393. <https://doi.org/10.1016/j.ccell.2016.02.001>
- Johnson, K. J., Cullen, J., Barnholtz-Sloan, J. S., Ostrom, Q. T., Langer, C. E., Turner, M. C., McKean-Cowdin, R., Fisher, J. L., Lupo, P. J., Partap, S., Schwartzbaum, J. A., & Scheurer, M. E. (2014). Childhood Brain Tumor Epidemiology: A Brain Tumor Epidemiology Consortium Review. *Cancer Epidemiology Biomarkers & Prevention*, *23*(12), 2716–2736. <https://doi.org/10.1158/1055-9965.epi-14-0207>
- Keough, M. B., & Monje, M. (2022). Neural Signaling in Cancer. *Annual Review of Neuroscience*, *45*(1), 199–221. <https://doi.org/10.1146/annurev-neuro-111020-092702>

- Lane-Reticker, S. K., Kessler, E., Muscato, A. J., Kim, S. Y., Doench, J. G., Yates, K. B., Manguso, R. T., & Dubrot, J. (2023). Protocol for in vivo CRISPR screening using selective CRISPR antigen removal lentiviral vectors. *STAR Protocols*, 4(1), 102082–102082. <https://doi.org/10.1016/j.xpro.2023.102082>
- Langer, L. F., Ward, J. M., & Archer, T. K. (2019). Tumor suppressor SMARCB1 suppresses super-enhancers to govern hESC lineage determination. *ELife*, 8. <https://doi.org/10.7554/elife.45672>
- Lau, C., Chamberlain, R., & Mahendraraj, K. (2015). Atypical teratoid rhabdoid tumors: a population-based clinical outcomes study involving 174 patients from the Surveillance, Epidemiology, and End Results database (1973–2010). *Cancer Management and Research*, 301. <https://doi.org/10.2147/cmar.s88561>
- Lee, R. S., Stewart, C., Carter, S. L., Ambrogio, L., Cibulskis, K., Sougnez, C., Lawrence, M. S., Auclair, D., Mora, J., Golub, T. R., Biegel, J. A., Getz, G., & Charles W.M. Roberts. (2012). A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. *Journal of Clinical Investigation*, 122(8), 2983–2988. <https://doi.org/10.1172/jci64400>
- Lin, G. L., Wilson, K. M., Ceribelli, M., Stanton, B. Z., Woo, P. J., Kreimer, S., Qin, E. Y., Zhang, X., Lennon, J., Nagaraja, S., Morris, P. J., Quezada, M., Gillespie, S. M., Dubeau, D. Y., Michalowski, A. M., Shinn, P., Guha, R., Ferrer, M., Klumpp-Thomas, C., Michael, S., ... Monje, M. (2019). Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. *Science translational medicine*, 11(519), eaaw0064. <https://doi.org/10.1126/scitranslmed.aaw0064>
- Lu, Y., Chan, Y.-T., Tan, H.-Y., Li, S., Wang, N., & Feng, Y. (2020). Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. *Molecular Cancer*, 19(1). <https://doi.org/10.1186/s12943-020-01197-3>
- Lyseng-Williamson, K. A. (2016). Idebenone: A Review in Leber's Hereditary Optic Neuropathy. *Drugs*, 76(7), 805–813. <https://doi.org/10.1007/s40265-016-0574-3>

- Martínez-Reyes, I., & Chandel, N. S. (2021). Cancer metabolism: looking forward. *Nature Reviews Cancer*, 21(10), 669–680. <https://doi.org/10.1038/s41568-021-00378-6>
- Mathiowetz, A. J., Roberts, M. A., Morgens, D. W., Olzmann, J. A., & Li, Z. (2023). Protocol for performing pooled CRISPR-Cas9 loss-of-function screens. *STAR Protocols*, 4(2), 102201. <https://doi.org/10.1016/j.xpro.2023.102201>
- Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2021). Cell cycle control in cancer. *Nature Reviews Molecular Cell Biology*, 23. <https://doi.org/10.1038/s41580-021-00404-3>
- Mayoh, C., Mao, J., Xie, J., Tax, G., Chow, S.-O., Cadiz, R., Pazaky, K., Barahona, P., Ajuyah, P., Trebilcock, P., Malquori, A., Gunther, K., Avila, A., Yun, D. Y., Alfred, S., Gopalakrishnan, A., Kamili, A., Wong, M., Cowley, M. J., & Jessop, S. (2023). High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer. *Cancer Research*, 83(16), 2716–2732. <https://doi.org/10.1158/0008-5472.can-22-3702>
- Meier, T., Perlman, S. L., Rummey, C., Coppard, N. J., & Lynch, D. R. (2011). Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. *Journal of Neurology*, 259(2), 284–291. <https://doi.org/10.1007/s00415-011-6174-y>
- Mittal, P., & Roberts, C. W. M. (2020). The SWI/SNF complex in cancer — biology, biomarkers and therapy. *Nature Reviews Clinical Oncology*, 17(7), 435–448. <https://doi.org/10.1038/s41571-020-0357-3>
- Mody, R. (2023, November 8). *Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)*. Identifier NCT03526250. <https://clinicaltrials.gov/ct2/show/NCT03526250>



- Montalto, F. I., & De Amicis, F. (2020). Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma. *Cells*, 9(12), 2648. <https://doi.org/10.3390/cells9122648>
- National Library of Medicine (U.S.). (2011, January -). *Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)*. Identifier NCT00758225. <https://clinicaltrials.gov/ct2/show/NCT00758225>
- National Library of Medicine (U.S.). (2020, April 1). *Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors*. Identifier NCT03387020. <https://clinicaltrials.gov/ct2/show/NCT03387020>
- National Library of Medicine (U.S.). (2023, June 2). *Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer (CYCLONE 1)*. Identifier NCT04408924. <https://clinicaltrials.gov/ct2/show/NCT04408924>
- National Library of Medicine (U.S.). (2023, March 13). *Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer*. Identifier NCT05112536. <https://clinicaltrials.gov/ct2/show/NCT05112536>
- National Library of Medicine (U.S.). (2023, October 11). (2020, November 9). *A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma*. Identifier NCT04238819. <https://clinicaltrials.gov/ct2/show/NCT04238819>
- National Library of Medicine (U.S.). (2023, October 10). *Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors*. Identifier NCT03709680. <https://clinicaltrials.gov/ct2/show/NCT03709680>
- Ong, M. S., Deng, S., Halim, C. E., Cai, W., Tan, T. Z., Huang, R. Y.-J., Sethi, G., Hooi, S. C., Kumar, A. P., & Yap, C. T. (2020). Cytoskeletal Proteins in Cancer and Intracellular Stress: A Therapeutic Perspective. *Cancers*, 12(1), 238. <https://doi.org/10.3390/cancers12010238>

- Ostrom, Q. T., Chen, Y., M. de Blank, P., Ondracek, A., Farah, P., Gittleman, H., Wolinsky, Y., Kruchko, C., Cohen, M. L., Brat, D. J., & Barnholtz-Sloan, J. S. (2014). The descriptive epidemiology of atypical teratoid/rhabdoid tumors in the United States, 2001-2010. *Neuro-Oncology*, *16*(10), 1392–1399. <https://doi.org/10.1093/neuonc/nou090>
- Park, Y., Obiang-Obounou, B. W., Lee, K., Choi, J., & Jang, B. (2018). AZD1208, a pan-Pim kinase inhibitor, inhibits adipogenesis and induces lipolysis in 3T3-L1 adipocytes. *Journal of Cellular and Molecular Medicine*, *22*(4), 2488–2497. <https://doi.org/10.1111/jcmm.13559>
- Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022). PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? *Frontiers in Oncology*, *12*. <https://doi.org/10.3389/fonc.2022.819128>
- Perera, N., & Koralege, R. S. H. (2023). High throughput screening. *Elsevier EBooks*. <https://doi.org/10.1016/b978-0-12-824315-2.01035-6>
- Richardson, E., Ho, B., & Huang, A. (2018). Atypical Teratoid Rhabdoid Tumour : From Tumours to Therapies. *Journal of Korean Neurosurgical Society*, *61*(3), 302–311. <https://doi.org/10.3340/jkns.2018.0061>
- Roberts, C. W. M., Galusha, S. A., McMenamin, M., Fletcher, C. D. M., & Orkin, S. H. (2000). Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. *Proceedings of the National Academy of Sciences of the United States of America*, *97*(25), 13796–13800. <https://doi.org/10.1073/pnas.250492697>
- Rorke, L. B., Packer, R. J., & Biegel, J. A. (1996). Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. *Journal of Neurosurgery*, *85*(1), 56–65. <https://doi.org/10.3171/jns.1996.85.1.0056>
- Santio, N. M., Landor, S. K. J., Vahtera, L., Ylä-Pelto, J., Paloniemi, E., Imanishi, S. Y., Corthals, G. L., Markku Varjosalo, Ganesh babu Manoharan, Uri, A., Urban Lendahl, Sahlgren, C., & Koskinen, P. J. (2016). Phosphorylation of Notch1 by Pim kinases promotes oncogenic signaling in

- breast and prostate cancer cells. *Oncotarget*, 7(28), 43220–43238.  
<https://doi.org/10.18632/oncotarget.9215>
- Saraon, P., Pathmanathan, S., Snider, J., Lyakisheva, A., Wong, V., & Stagljar, I. (2021). Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches. *Oncogene*, 40(24), 4079–4093. <https://doi.org/10.1038/s41388-021-01841-2>
- Scheff, J. D., Almon, R. R., DuBois, D. C., Jusko, W. J., & Androulakis, I. P. (2011). Assessment of Pharmacologic Area Under the Curve When Baselines are Variable. *Pharmaceutical Research*, 28(5), 1081–1089. <https://doi.org/10.1007/s11095-010-0363-8>
- Shalem, O., Sanjana, N. E., & Zhang, F. (2015). High-throughput functional genomics using CRISPR-Cas9. *Nature Reviews. Genetics*, 16(5), 299–311. <https://doi.org/10.1038/nrg3899>
- Studzinski, G. P., & Danilenko, M. (2005, January 1). *CHAPTER 92 - Differentiation and the Cell Cycle* (D. Feldman, Ed.). ScienceDirect; Academic Press.  
<https://www.sciencedirect.com/science/article/abs/pii/B9780122526879500966>
- Sun, C. X., Daniel, P., Bradshaw, G., Shi, H., Loi, M., Chew, N., Parackal, S., Tsui, V., Liang, Y., Koptyra, M., Adjumain, S., Sun, C., Chong, W. C., Fernando, D., Drinkwater, C., Tourchi, M., Habarakada, D., Sooraj, D., Carvalho, D., Storm, P. B., ... Firestein, R. (2023). Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities. *Cancer cell*, 41(4), 660–677.e7. <https://doi.org/10.1016/j.ccell.2023.03.007>
- Szymański, P., Markowicz, M., & Mikiciuk-Olasik, E. (2011). Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests. *International Journal of Molecular Sciences*, 13(1), 427–452. <https://doi.org/10.3390/ijms13010427>
- Tai, K. K., Pham, L., & Truong, D. D. (2011). Idebenone Induces Apoptotic Cell Death in the Human Dopaminergic Neuroblastoma SHSY-5Y Cells. *Neurotoxicity Research*, 20(4), 321–328.  
<https://doi.org/10.1007/s12640-011-9245-z>
- Terada, Y., Jo, N., Arakawa, Y., Sakakura, M., Yamada, Y., Ukai, T., Kabata, M., Mitsunaga, K., Mineharu, Y., Ohta, S., Nakagawa, M., Miyamoto, S., Yamamoto, T., & Yamada, Y. (2019). Human

- Pluripotent Stem Cell-Derived Tumor Model Uncovers the Embryonic Stem Cell Signature as a Key Driver in Atypical Teratoid/Rhabdoid Tumor. *Cell Reports*, 26(10), 2608-2621.e6. <https://doi.org/10.1016/j.celrep.2019.02.009>
- Torchia, J., Golbourn, B., Feng, S., Ho, K. C., Sin-Chan, P., Vasiljevic, A., Norman, J. D., Guilhamon, P., Garzia, L., Agamez, N. R., Lu, M., Chan, T. S., Picard, D., de Antonellis, P., Khuong-Quang, D.-A., Planello, A. C., Zeller, C., Barsyte-Lovejoy, D., Lafay-Cousin, L., & Letourneau, L. (2016). Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. *Cancer Cell*, 30(6), 891–908. <https://doi.org/10.1016/j.ccell.2016.11.003>
- Venkataraman, S., Alimova, I., Tello, T., Harris, P., Knipstein, J., Donson, A. M., Foreman, N. K., Liu, A. K., & Rajeev Vibhakar. (2012). Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells. *Journal of Neuro-Oncology*, 107(3), 517–526. <https://doi.org/10.1007/s11060-011-0795-y>
- Vulin, M., Jehanno, C., Sethi, A., Correia, A. L., Obradović, M. M. S., Couto, J. P., Coissieux, M. M., Diepenbruck, M., Preca, B. T., Volkmann, K., der Maur, P. A., Schmidt, A., Müntz, S., Sauter, L., Kloc, M., Palafox, M., Britschgi, A., Unterreiner, V., Galuba, O., Claerr, I., ... Bentires-Alj, M. (2022). A high-throughput drug screen reveals means to differentiate triple-negative breast cancer. *Oncogene*, 41(39), 4459–4473. <https://doi.org/10.1038/s41388-022-02429-0>
- Wang, J. Y., & Doudna, J. A. (2023). CRISPR technology: A decade of genome editing is only the beginning. *Science*, 379(6629). <https://doi.org/10.1126/science.add8643>
- Willems, E., Dedobbeleer, M., Digregorio, M., Lombard, A., Lumapat, P. N., & Rogister, B. (2018). The functional diversity of Aurora kinases: a comprehensive review. *Cell Division*, 13(7). <https://doi.org/10.1186/s13008-018-0040-6>
- Wilson, B. G., Wang, X., Shen, X., McKenna, E. S., Lemieux, M. E., Cho, Y.-J., Koellhoffer, E. C., Pomeroy, S. L., Orkin, S. H., & Roberts, C. W. M. (2010). Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation. *Cancer Cell*, 18(4), 316–328. <https://doi.org/10.1016/j.ccr.2010.09.006>

- Xie, J., Wang, C., & Gore, J. C. (2016). High Throughput Screening for Colorectal Cancer Specific Compounds. *Combinatorial chemistry & high throughput screening*, 19(3), 180–188. <https://doi.org/10.2174/1386207319666160202120928>
- Yao, Y., & Dai, W. (2014). Genomic Instability and Cancer. *Journal of Carcinogenesis & Mutagenesis*, 05(02). <https://doi.org/10.4172/2157-2518.1000165>
- Ye, Y., Chen, X., & Zhang, W. (2021). Mammalian SWI/SNF Chromatin Remodeling Complexes in Embryonic Stem Cells: Regulating the Balance Between Pluripotency and Differentiation. *Frontiers in Cell and Developmental Biology*, 8. <https://doi.org/10.3389/fcell.2020.626383>
- Zaky, W., Dhall, G., Ji, L., Haley, K., Allen, J., Atlas, M., Bertolone, S., Cornelius, A., Gardner, S., Patel, R., Pradhan, K., Shen, V., Thompson, S., Torkildson, J., Sposto, R., & Finlay, J. L. (2013). Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid/rhabdoid tumors: The head start III experience. *Pediatric Blood & Cancer*, 61(1), 95–101. <https://doi.org/10.1002/pbc.24648>
- Zhang, X., Song, M., Kundu, J. K., Lee, M.-H., & Liu, Z.-Z. (2018). PIM Kinase as an Executional Target in Cancer. *Journal of Cancer Prevention*, 23(3), 109–116. <https://doi.org/10.15430/jcp.2018.23.3.109>
- Zuo, E., Cai, Y. J., Li, K., Wei, Y., Wang, B. A., Sun, Y., Liu, Z., Liu, J., Hu, X., Wei, W., Huo, X., Shi, L., Tang, C., Liang, D., Wang, Y., Nie, Y.-H., Zhang, C.-C., Yao, X., Wang, X., & Zhou, C. (2017). One-step generation of complete gene knockout mice and monkeys by CRISPR/Cas9-mediated gene editing with multiple sgRNAs. *Cell Research*, 27(7), 933–945. <https://doi.org/10.1038/cr.2017.81>